Genmab A (GMAB) Restructuring Costs (2024 - 2026)

Genmab A's (GMAB) quarterly Restructuring Costs came in at -$45.0 million in Q1 2026, down 15.38% on a QoQ basis from -$39.0 million in Q3 2024.

Genmab A (GMAB) Restructuring Costs (2024 - 2026) Analysis & Trends

Genmab A (GMAB) has 2 years of Restructuring Costs data on file, last reported at -$45.0 million in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to -$45.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.0 million (changed N/A YoY) and the FY2025 annual result came in at -$185.0 million, down 478.12% from the prior year.
Restructuring Costs fell to -$45.0 million in Q1 2026, from -$39.0 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of -$36.0 million in Q2 2024 to a low of -$45.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Genmab A	2.05 Bn	548.77 Mn	1.07 Bn

Download Data